Cancer drug fails to show better patient survival

03/8/2005 | Reuters

Seattle-based Cell Therapeutics reported a late-stage trial failed to show its experimental lung cancer drug extended patient survival any more than standard chemotherapy. The company said the survival rate for patients with non-small cell lung cancer who received a combination of Xyotax and carboplatin was the same as patients who received paclitaxel in combination with carboplatin.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ